, spending grew to 3-4 % a year, but during the last quarter of 2013, growth was at 5.6%, the highest in 10 years. It is, however, unclear how much of this is due to the economy and ACA. The variation of clinical appropriateness within a diagnosis is as wide as the variation of appropriateness between diagnoses. The focus of the ACA was on coverage and access with limited attention on delivery of care. The ACA created a few pilot projects through Accountable Care Organizations (ACOs), such as, Medical Homes, bundled payments, Patient Centered Outcome Research Institute (PCORI), but it is too soon to conclude that these all have been successful. The bundled payment encourages efficiency within the bundled services but offers no reward for quality or outcome. Physicians' payment system desperately needs reform. Too much attention has been given to Sustainable Growth Rate (SGR), rather than finding ways to pay for quality and efficiency. Reform of liability insurance looking into ways to protect physicians and institutions that practice conservative medicine is also needed. Arbitrary caps on pain and suffering will not improve quality of care. She suggested considering a 'quid pro quo' strategy by giving protection in liability risks to those who adopt Institute of Medicine (IOM) patient-safety guidelines and evidence-based clinical practice protocols. Given the current trend of enrollments for coverage, the Congressional Budget Office (CBO) estimates that 31 million people will remain uninsured in 2023. Many unknowns are ahead: impact of the newly insured on healthcare services utilizations, and on the use of prescriptions drugs.
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Panel Presentation
The panel discussion moderated by Richard Bagger, Senior Vice President, Celgene, and participated by Indranil Bagchi, Vice President, Pfizer, Anita Burrell, Associate Vice President, Sanofi, and Joseph DiCesare, Global Head, Strategic Pricing & Access, Novartis, concentrated around the issues of pharmaceutical re-imbursements on a global perspective. In his opening remarks, Richard Bagger laid out the role of pharmaceutical drugs in containing the overall healthcare cost and in enhancing longevity and quality of lives. He described the challenges brought by the ACA in the USA and by technology assessment thresholds around the globe. He also described the role pharmaceutical innovation in enhancing societal value.
In his opening remarks, Indranil Bagchi described a perfect storm scenario, in one hand there is always a budget constraint in reimbursing expensive drugs by payers and on the other hand the pharmaceutical companies' need for margin in developing their product portfolio. Drug development is driven by unmet need, and currently many companies are developing specialty drugs and orphan drugs because of huge unmet need in this space. Many of these drugs are developed in collaboration with specialized research organizations and academia. In the early days 90% of the data on drug development were generated in house and now-a-days, because of external partners in drug development, only about 10% of the data is generated in house. These drugs are expensive due to high development cost. Anita Burrell described the value chain in drug development, and its role in value based pricing. In his opening remarks, Joseph DiCesare explained the evidence based value as analyzed by outcome data. The clinical data collected during the drug development is not enough to get market access as demanded by the payers and prescribers. These stakeholders require real world data of efficacy of the drug in a large patient base.
In response to a question on the challenges and opportunities of orphan drugs, Indranil Bagchi responded that these drugs are safe and efficacious but on the standard technological assessment measures, these drugs do not perform well for small population because those standards are set based on overall social welfare. The pharmaceutical companies need to find better ways to define value of their products. In response to a question on the role of value based pricing and reference pricing on competition and on investment in the R&D effort, the panel members discussed the underlying limitations of practical use of these concepts.
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In this paper we develop a framework on which to model drug development at the intersection of rare disease legislation and increasing comparative effectiveness research standards for orphan drugs. We review the American Recovery and Reinvestment Act of 2009 that allocated $1.1 billion for comparative effectiveness research (CER). Complementing this act, 2010 saw the establishment of the Patient-Centered Outcomes Research Institute (PCORI), to manage the funding and conduct of CER. Designed more for large patient populations, PCORI's proposed funding criteria of cost effective research has drawn concern from the rare disease community that fears the erosion of progress made over the past 30 years in public policy and funding of therapies for rare diseases. We show how the CER can be utilized in orphan drug developments. In recent years, the major research intensive biopharmaceutical companies (big pharma) have come face to face with a perfect storm of eroding profit margins from blockbuster expiration and generic competition coupled with growing R&D expenses and declining advances in truly novel therapeutics. With long-term research divisions shed in favor of short-term outsourcing options and with public good-will at historic lows, industry innovators have sought to reinvent the model of big pharma, its relationship in public-private partnerships, and the role of technology and technology policy in reform. In this paper, we highlight a number of the major alliances reshaping the industry and the role of government, research institutions, and other players in the public-private interface in these endeavors. In particular, this paper looks beyond traditional biotechnology partnerships and focuses instead on the developing consortia between biopharmaceutical companies and with clinical research organizations and academic institutions. We examined each alternative model of alliance, identified specific hurdles and potentials for increased productivity.
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